Sanuwave Health, Inc. (SNWV) Stock Price & Analysis
Sanuwave Health, Inc. (SNWV) rose 0.17% to USD 5.93 as of July 25, 2026 at 19:47 UTC, according to Nexqual real-time market data.
SNWV last closed at USD 5.92; the session ranged USD 5.82–6.16 on volume of 109,100 shares. Market capitalization is $50.99M, with a 52-week range of USD 5.77–46.59 (NGM). Source: Nexqual, July 25, 2026 at 19:47 UTC.
Key Statistics (as of July 25, 2026 at 19:47 UTC)
| Price | USD 5.93 |
|---|---|
| Change | ▲ 0.17% (up) |
| Previous Close | USD 5.92 |
| Open | USD 5.9 |
| Day Range | USD 5.82 – 6.16 |
| 52-Week Range | USD 5.77 – 46.59 |
| Volume | 109,100 shares |
| Market Cap | $50.99M |
| Exchange | NGM |
Technical Analysis (SNWV)
Nexqual's technical model rates SNWV "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 19:47 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 28.12 (oversold) |
| vs SMA50 | Below (USD 12.12) |
| MACD | -1.71 (negative) |
Analyst Ratings (SNWV)
Wall Street analysts rate SNWV "None", per Nexqual as of July 25, 2026 at 19:47 UTC.
| Consensus Rating | None |
|---|---|
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (SNWV)
| Next Earnings Date | 2026-08-07 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD 0.03 vs est 0.17 ▼ miss |
| 2025-09-30 | USD 0.46 vs est 0.32 ▲ beat |
| 2025-06-30 | USD 0.01 vs est -0.09 ▲ beat |
Source: Nexqual, July 25, 2026 at 19:47 UTC.
Financials & Fundamentals (SNWV)
| Total Revenue | $44.34M |
|---|---|
| Revenue Growth (YoY) | +3.10% |
| Gross Margin | +76.74% |
| Operating Margin | -11.68% |
| Profit Margin | +37.20% |
| Debt / Equity | 1,205.88 |
| Current Ratio | 1.31 |
| Total Cash | $10.78M |
| Total Debt | $22.16M |
| Free Cash Flow | $-5.50M |
Source: Nexqual, July 25, 2026 at 19:47 UTC.
Financial Health Score (SNWV)
Nexqual rates Sanuwave Health, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 19:47 UTC.
| Growth | Mixed — Revenue +3.1% YoY (latest Q), slow |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Critical — $11M cash vs $22M debt |
| Cash Flow | Weak — FCF negative: -$6M, burning cash |
| Efficiency | Mixed — No data |
Ownership (SNWV)
| Insider Ownership | +1.31% |
|---|---|
| Institutional Ownership | +47.10% |
| Shares Outstanding | 8.60M |
| Float | 5.79M |
| Short % of Float | +10.78% |
Source: Nexqual, July 25, 2026 at 19:47 UTC.
Leadership (SNWV)
Sanuwave Health, Inc. is led by Morgan C. Frank (age 53), CEO & Chairman, per Nexqual as of July 25, 2026 at 19:47 UTC.
| CEO & Chairman | Morgan C. Frank (age 53) |
|---|---|
| Chief Operating Officer | Daniel Coyle (age 34) |
| Executive Vice President of Sales - U.S. Wound | Timothy Wern (age 57) |
| CFO & Secretary | Peter Sorensen (age 32) |
| Chief Technology Officer | Christopher Cook |
Major Backers & Investors (SNWV)
Notable institutional backers of Sanuwave Health, Inc. include Opaleye Management Inc., AWM Investment Company, Inc., Praetorian PR LLC, according to Nexqual as of July 25, 2026 at 19:47 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Opaleye Management Inc. | 11.48% |
| AWM Investment Company, Inc. | 5.32% |
| Praetorian PR LLC | 4.1% |
| Solas Capital Management, LLC | 3.36% |
| Stifel Financial Corporation | 2.94% |
| UBS Group AG | 2.46% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.59% |
| Vanguard Group | 8.49% |
| Geode Capital | 2.01% |
| State Street | 1.64% |
Source: Nexqual, July 25, 2026 at 19:47 UTC.
From Sanuwave Health, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- SANUWAVE Health, Inc. operates as a medical device company in the United States and internationally.
- It focuses on the commercialization of regenerative medicines through noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures.
- The company markets UltraMist system, a medical device that uses non-thermal ultrasound to treat tissues using a fluid mist to transmit energy in a non-contact and pain free way for use in the treatment of acute and chronic wounds.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CDIX | Cardiff Lexington Corporation | USD 0.7 | ▲ 27.27% |
| AMNC | Amincor Inc | USD 0.03 | ▲ 0% |
| BLTH | American Battery Materials Inc. | USD 6 | ▼ 0.83% |
| SGLY | Singularity Future Technology L | USD 0.27 | ▲ 3.31% |
| PRSI | Portsmouth Square, Inc. | USD 6.8 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 19:47 UTC. This page is informational and not investment advice.